Quote:

---

Dr. Jay Circling Back to "HIV", but with a twist.

00:24:03 Dr. Jay Lalezari:

And the consensus with the HIV consultants has been that we look, go circle back to HIV, but instead of looking at leronlimab as an antiviral, we are looking now at leronlimab as a modulator of immune activation. Is that a relevant endpoint? It is , because immune activation inflammation is the primary driver of mortality in HIV patients. Strokes, heart attacks, liver, kidney. It is unfortunately a much more difficult endpoint to assess than simply following an HIV viral load, but it is kind of in the wheelhouse of what we're believing leronlimab is capable of. So, the proposed next study is to look at leronlimab in HIV positive ambulatory subjects. We know it's safe in that group. In individuals who demonstrate elevations of immune activation markers. So known evidence of immune activation inflammation. And then we're tentatively looking at both doses 350 and 700mg and looking at a nested placebo arm so that at the end of 24 weeks of treatment, we can at least get a real measurement of whether leronlimab has moved the needle there or not.

---

The Making of a Platform Drug

It's not just for HIV patients.
Thank you My69z, I appreciate your posts and your comments.